Gottlieb: FDA Will Act If Brand Makers Mislead Public On Biosimilar Safety

FDA Commissioner Scott Gottlieb tweeted that FDA continues to be concerned that brand biologics companies are misleading the public about the safety and effectiveness of biosimilars, and he warned the agency will take action if it determines a company is purposely creating confusion. The agency chief’s tweet Thursday (Jan. 10) linked to a Washington Post article that highlighted recent statements made by brand-friendly, industry-funded groups that called into question the safety of biosimilars and non-medical switching. Those statements allege...